great stuff


I wonder when it will start trading? Should be soon I think

That shell looks to be as clean as a whistle. The float looks like it equals zero, so liquidity could be a problem lol!

Therabiogen merges into Kushi Resource, Inc. shell:

http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6900959

SCRK will get 2 bucks for every unit sold


theramax should be in wallgreens within the month.

http://theramaxrelief.com/

10K: http://www.sec.gov/Archives/edgar/data/1140299/000114029909000005/0001140299-09-000005-index.idea.htm

should be soon

I guess I got deleted for lack of activity.

Trying to get mod position back...

I knew Therabiogen would reappear eventually. Can't buy shares yet though.

Spring Creek Capital Announces Logistics Agreement Between Stratis Healthcare, Inc. and TheraBiogen, Inc.

* Press Release
* Source: Spring Creek Capital Corporation
* On Tuesday July 21, 2009, 1:26 pm EDT

*
Buzz up! 0
* Print

*
Companies:
o Spring creek capital corp

Spring Creek Capital Corp. (OTC.BB:SCRK - News), a Nevada corporation, announced today that Stratis Healthcare, Inc., a portfolio investment company of Spring Creek, has entered into an agreement with TheraBiogen, Inc. to provide inventory, distribution and logistics services for the distribution of TheraBiogen's TheraMax(TM) products to major U.S. retailers. Stratis Healthcare, Inc. is engaged in the business of providing end-to-end logistics services for small to mid-size medical product manufacturers. Stratis utilizes strategic partnerships to warehouse, provide inventory control and monitoring, and distribute products on a global basis. Its market niche is in providing market specific knowledge for the storage, handling, and distribution of medical products.
Related Quotes
Symbol Price Change
SCRK.OB 1.63 -0.01
Chart for SPRING CREEK CAPITAL
{"s" : "scrk.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

TheraBiogen is the exclusive North American manufacturer and distributor of homeopathic nasal spay cold, flu and allergy relief products which contain no zinc, and which are distributed under the TheraMax(TM) trade name. The TheraMax(TM) products are being introduced to the marketplace in the second half of 2009 through a number of pharmaceutical distributors and retailers. The TheraMax(TM) products are proven to provide fast, effective relief for sufferers of colds, flus and allergies in a short period of time. They are formulated to avoid previously known health side effects as stated by the FDA such as those caused by zinc-based products.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risks that could cause actual performance and results of operations to differ materially from those anticipated. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new ventures, as well as other factors set forth in Spring Creek Capital's most recently filed Form 10-K and Form 10-Q reports. The forward-looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. Spring Creek Capital assumes no obligation to update the statements contained in this release.

10K:

http://www.secinfo.com/DB/SEC/2009-000/1140/299-0000/03-002.pdf

Tera Trema ( now Therabiogen ) never traded publically, so this will be like an IPO....only 25 shareholders at present. If they merge with CTNO, then they get instant liquidity...well, at least some anyways....

CTNO RM gets my vote, BOOYAH!!!

Chris ( Leaddog ) is into this one. Notice the highlighted part.

"On November 27, 2007, the Company borrowed the sum of $30,000 from Leaddog Capital, LP issuing a 2 year, convertible debenture at 4 percent interest, convertible into 4,200,000 shares of its common stock, at the discretion of the holder during the term of the debenture, and automatically at maturity. The funds were used to reinstate the Company to good standing with its State of incorporation (Nevada) and for working capital.
On August 29, 2008, the Company received an additional $200,000 investment from Leaddog Capital, LP and issued a 2 year convertible debenture at 12 percent interest. The debenture is convertible into common
stock of the Company at any time after 20 days from the first listing of the Company?s common stock for trading, at a conversion price per share equal to 75 percent of the lowest closing bid price for the common shares in the prior 20 trading days, but not less than $0.01 and not more than $0.10 per share. The funds were used in part for the initial license fee payment of $150,000 to Nasal Therapeutics, Inc. The balance of the funds have been used as working capital."

Will they get a symbol and list themselves? Or will the they merge into CTNO or other clean shell that is already trading?

Has anyone seen Chris Messalas?

Dr. Hensley developed Zicam...which seems to have run into some problems with loss of smell in a very small group. Now Theramax appears to be the next generation...without zinc.

"THERAMAX? Cold Relief homeopathic nasal spray is the next generation Zicam cold remedy product. Zicam, which was developed by Dr. Hensley in the late 1990?s, is a highly successful product with sales exceeding US$100,000,000 in 2006. However, in recent years, the use of zinc in the Zicam product has come under fire. In 2003, reports began to surface that a small number of Zicam users suffered a condition known as anosmia, or total loss of smell. It has since been demonstrated that Zicam is safe and does not cause anosmia. However, these reports have left questions in the minds of consumers creating a huge market for a Zicam-type product that does not contain zinc.
Common colds are caused primarily by rhinoviruses and coronaviruses. Rhinoviruses infect nasal cells by attaching to ICAM receptor sites on the nasal membrane. Zicam reduces the duration of rhinovirus common cold by inhibiting the ability of the rhinovirus to bind to and infect nasal cells. The ionic zinc in Zicam binds to the rhinovirus ICAM attachment site and inhibits the rhinovirus attachment to ICAM receptors. However, ICAM levels on nasal cells are increased in the presence of rhinovirus making it likely that a substantial amount of rhinovirus/ICAM interactions occur, even in the presence of Zicam. This most likely results in incomplete suppression of common cold infections and opens the door for the development of new Zicam type technologies.

THERAMAX? Cold Relief is superior to other homeopathic cold remedies on a variety of levels. Similar to other remedies, the active ingredients of THERAMAX? Cold Relief also binds to the rhinovirus ICAM attachment site inhibiting rhinovirus attachment to ICAM receptors. However, unlike Zicam, THERAMAX? Cold Relief ingredients also inhibits the ability of rhinovirus to increase the amount of ICAM receptors on the nasal membrane. Furthermore, the actives in THERAMAX? Cold Relief also inhibits the entry coronaviruses making it effective for coronavirus common colds as well. The fact that the actives in THERAMAX? Cold Relief decreases ICAM levels and inhibits both rhinovirus and coronavirus should result in a more complete suppression of common cold infections than what is seen with Zicam. Human studies on THERAMAX? Cold Relief are still a few months from being initiated. However, based on in vitro data, preliminary human clinical data and our experience with Zicam, we expect THERAMAX? Cold Relief to be much more effective than Zicam at reducing the duration of the common cold. Patents protecting the THERAMAX? Cold Relief intellectual property have been filed with the United States Patent and Trademark Office. "

Charles B. Hensley, Ph.D. Chairman and Chief Executive Officer



Prior to forming PRB Pharmaceuticals, Dr. Hensley was president of Zengen, a California biotech company specializing in anti-inflammatory medications. Dr. Hensley was a founder and Chief of Research and Scientific Affairs at Gel Tech, LLC, a joint venture between BioDelivery Technologies, Inc., and Gum Tech International, a NASDAQ publicly traded company. While at BioDelivery Technologies, Dr. Hensley invented Zicam® cold remedy, currently the most effective OTC remedy for the common cold on the market. From 1997 to 1999, Dr. Hensley served as Chairman of BioDelivery Technologies, Inc., which was acquired by Zengen in March 2000. From 1994 to 1997, Dr. Hensley served as Chairman of Biotem Cytotechnologies. Dr. Hensley received his Bachelor of Science degree in pre-med/Zoology from the University of Oklahoma and received his Ph.D. in Physiology and Biophysics at the University of Southern California School of Medicine. He completed his postdoctoral fellowship at the University of Southern California School of Medicine where he specialized in the mechanism of pharmaceutical drugs on regulation of gene expression

http://www.prbpharmaceuticals.com/prb_about.php?i_id=3

Nasal Therapeutics to Enter Migraine Headache Market With New Migraine Relief Homeopathic...
Tue Dec 4, 2007 10:58am EST

Email | Print |
Share
| Reprints | Single Page | Recommend (2)
[-] Text [+]

Nasal Therapeutics to Enter Migraine Headache Market With New Migraine Relief
Homeopathic Nasal Spray

LOS ANGELES, Dec. 4 /PRNewswire/ -- Nasal Therapeutics, Inc. announced today plans to enter the over-the-counter market with a new migraine relief homeopathic nasal spray. The nasal spray is scheduled to hit the shelves in the spring of 2008. Nasal Therapeutics, Inc., a subsidiary of Hensley Group, will launch a line of homeopathic nasal sprays over the next year which will include remedies for allergy, cold and flu. "There are approximately thirty million migraine sufferers in the United States alone", commented Dr. Charles Hensley, Inventor of Zicam Cold Remedy and Chairman of Hensley Group. "Migraine attacks are severe, come on suddenly and are often debilitating. Nasal sprays are the delivery system of choice when it comes to conditions that require rapid relief as they work much faster than oral formulations." "The development of the technology behind the new migraine product was actually quite serendipitous", added Hensley. "While working with intracellular mediators involved in the development of common colds, our scientists discovered that these same compounds are putative causative factors in the genesis and maintenance of migraine attacks. Since they were already developing nasal delivery compounds to address this therapeutic target, it was a natural to pursue a therapy for migraine attack," he continued.

About Nasal Therapeutics

Nasal Therapeutics develops and markets homeopathic nasal sprays for such conditions as common cold, influenza, allergy and migraine. The company is based on the concept that nasal delivery is the fastest, most effective way to deliver over-the-counter medicines to the site of therapeutic action. Nasal therapeutics was incorporated in 2007 and is in the process of closing its first round of financing.
For further information please contact:
Investor Relations at ir@nasal-theraeutics.com


About Hensley Group
Hensley Group controls a diverse group of subsidiary companies engaged in
Pharmaceuticals, Biotechnology, Cosmetics, Consulting, Media Marketing and
Entertainment and has offices in Los Angeles, Hong Kong, Shanghai and Tokyo.
SOURCE Nasal Therapeutics, Inc.

Natasha Nelson of NN Public Relations, +1-949-548-2227,
Natasha@nnpublicrelations.com, for Nasal Therapeutics, Inc.

Formerly Terra Trema: http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=4999182

Now this most interesting:

Item 8.01. Other Events.
On November 19, 2007, our Board authorized the execution by its wholly owned subsidiary Environmental Testing Laboratories, Inc. (“ETL”) of a Memorandum of Understanding (the “MOU”) for a potential merger of ETL with and into Terra Trema, Inc., a public company. The MOU was executed by ETL on November 19, 2007. If consummated, the merger would result in Terra Trema issuing additional shares of its common stock to the Company such that the Company would own 80% of the shares of Terra Trema. The MOU is not binding on any party thereto, and a merger of ETL into Terra Trema would be subject to the terms and conditions of a definitive agreement between the parties, which the Company would be required to approve as the sole shareholder of ETL. As of the date of this Report, the Company is negotiating a definitive agreement for such a merger, but such an agreement has not been completed.
Kelly T. Hickel, formerly our Chief Executive Officer and a director, and currently a consultant to the Company, is a director and officer of ETL.

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6019299

Filings brought up to date:

http://yahoo.brand.edgar-online.com/default.aspx?cik=1140299

Not even publicly trading yet. Old bankrupt shell Terra Trema Inc.